Home > Publications database > Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression. > print

001     130330
005     20240228143425.0
024 7 _ |a 10.18632/oncotarget.10729
|2 doi
024 7 _ |a pmid:27449098
|2 pmid
024 7 _ |a pmc:PMC5312160
|2 pmc
024 7 _ |a altmetric:10111986
|2 altmetric
037 _ _ |a DKFZ-2017-05409
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Pickl, Julia M A
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression.
260 _ _ |a [S.l.]
|c 2016
|b Impact Journals LLC
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1522136125_11125
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Prostate cancer is a heterogeneous disease. MiR-375 is a marker for prostate cancer progression, but its cellular function is not characterized. Here, we provide the first comprehensive investigation of miR-375 in prostate cancer. We show that miR-375 is enriched in prostate cancer compared to normal cells. Furthermore, miR-375 enhanced proliferation, migration and invasion in vitro and induced tumor growth and reduced survival in vivo showing that miR-375 has oncogenic properties in prostate cancer. On the molecular level, we provide the targetome and genome-wide transcriptional changes of miR-375 expression by applying a generalized linear model for Ago-RIP-Seq and RNA-Seq, and show that miR-375 is involved in tumorigenic networks and Polycomb regulation. Integration of tissue and gene ontology data prioritized miR-375 targets and identified the tumor suppressor gene CBX7, a member of Polycomb repressive complex 1, as a major miR-375 target. MiR-375-mediated repression of CBX7 was accompanied by increased expression of its homolog CBX8 and activated transcriptional programs linked to malignant progression in prostate cancer cells. Tissue analysis showed association of CBX7 loss with advanced prostate cancer. Our study indicates that miR-375 exerts its tumor-promoting role in prostate cancer by influencing the epigenetic regulation of transcriptional programs through its ability to directly target the Polycomb complex member CBX7.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Tichy, Diana
|0 P:(DE-He78)2ef631585610340ff425c9c31fcabd03
|b 1
|u dkfz
700 1 _ |a Kuryshev, Vladimir
|0 P:(DE-He78)cd1568106ba01cc0741f464d15267a9b
|b 2
|u dkfz
700 1 _ |a Tolstov, Yanis
|b 3
700 1 _ |a Falkenstein, Michael
|b 4
700 1 _ |a Schüler, Julia
|b 5
700 1 _ |a Reidenbach, Daniel
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Hotz-Wagenblatt, Agnes
|0 P:(DE-He78)2f34b89d62d5e5c651aa1e683844b092
|b 7
|u dkfz
700 1 _ |a Kristiansen, Glen
|b 8
700 1 _ |a Roth, Wilfried
|b 9
700 1 _ |a Hadaschik, Boris
|b 10
700 1 _ |a Hohenfellner, Markus
|b 11
700 1 _ |a Duensing, Stefan
|b 12
700 1 _ |a Heckmann, Doreen
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Sültmann, Holger
|0 P:(DE-He78)7483734fd8ab316391aa604c95f0e98a
|b 14
|e Last author
|u dkfz
773 _ _ |a 10.18632/oncotarget.10729
|g Vol. 7, no. 37, p. 59589 - 59603
|0 PERI:(DE-600)2560162-3
|n 37
|p 59589 - 59603
|t OncoTarget
|v 7
|y 2016
|x 1949-2553
909 C O |o oai:inrepo02.dkfz.de:130330
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)2ef631585610340ff425c9c31fcabd03
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)cd1568106ba01cc0741f464d15267a9b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)2f34b89d62d5e5c651aa1e683844b092
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)7483734fd8ab316391aa604c95f0e98a
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2016
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ONCOTARGET : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ONCOTARGET : 2015
920 1 _ |0 I:(DE-He78)B063-20160331
|k B063
|l Krebsgenomforschung
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 1
920 1 _ |0 I:(DE-He78)W180-20160331
|k W180
|l Bioinformatik (HUSAR)
|x 2
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B063-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)W180-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21